The leader in the business of psychedelics, Microdose is taking the next step in top-notch industry events with Wonderland 2022. Pulling off such a massive undertaking wouldn’t be possible without the support of our sponsors, they are crucial to both the Wonderland event and the future of the psychedelic medicine industry.
So it’s an honor for Microdose to announce Ninnion Therapeutics as a Platinum Sponsor for Wonderland: Miami 2022.
About Ninnion Therapeutics
Ninnion is a CNS pharmaceutical drug discovery & development company focused on next generation psychedelic molecules designed for the payer reimbursed market. The company has filed patent applications on its first molecule, NIN-S119, a psilocybin-like psychedelic molecule it will use in its upcoming human clinical trials in ischemic stroke recovery.
To build out its IP portfolio, Ninnion signed an exclusive AI drug discovery platform collaboration with a clinical focus on brain injury, chronic pain, inflammation, and addiction disorders. The company targets to develop multiple 3rd generation psychedelic molecules over the next five years, some of which it will develop in-house and others to either sell or partner with pharmaceutical companies to co-develop.
AI Drug Discovery Technology Platform
: Ninnion’s exclusive AI drug discovery platform partnership, is exclusive for creating next generation psychedelics which are New Chemical Entities for treating brain injury, inflammation, chronic pain and addiction In the next 5 years, Ninnion will create 10 or more novel, next generation psychedelic drug candidates with optimized pharmacological profiles, improved tolerability and safety.
NIN-S119 Ischemic Stroke Recovery: Ninnion has begun development of NIN-S119, our proprietary, short-acting substituted tryptamine to treat patients recovering from ischemic stroke. NIN-S119 will be used in conjunction with physical/occupational therapy to potentiate the ability to form new neuronal connections (synapses) and strengthen the connectivity of remaining brain cells engaged during therapy. NIN-S119 is postulated to enhance stroke recovery through inducing neuroplasticity, by stimulating the serotonin 2A (5-HT2A) receptor.
See more at https://ninnion.com/
